{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Adenocarcinoma of colon stage IV","patients with RAS-mutant advanced colorectal cancer","pazienti affetti da carcinoma colorettale con mutazioni di RAS","Colorectal Neoplasms","Rectal adenocarcinoma stage IV","Advanced Colorectal Cancer"],"disease":["Rectal Adenocarcinoma Stage Iv","Adenocarcinoma Of Colon Stage Iv","Colorectal Neoplasms","Patients With Ras-mutant Advanced Colorectal Cancer","Pazienti Affetti Da Carcinoma Colorettale Con Mutazioni Di Ras","Advanced Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2203440"],"location":["Italy"],"study_start_month":["11"],"keyword":["RAS-mutant","regorafenib"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer","description":"The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.","dates":{"creation":"2015-11-15"},"accession":"2203440","cross_references":{"ClinicalTrials___gov":["NCT02619435"],"EU Clinical Trials Register":["2015-001105-13"]}}